N EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.5 MILLION REGISTERED DI

CEL-SCI ANNOUNCES $1.5 MILLION REGISTERED DIRECT

Vienna, VA, Friday, March 9, 2017 - CEL-SCI Corporation

(NYSE MKT:CVM) today

announced it has entered into a definitive agreement with

institutional investors for an offering of shares of common stock

with gross proceeds of approximately $1.5 million in a registered

direct offering. The closing of the offering is expected to take

place on or about March 14, 2017, subject to the satisfaction of

customary closing conditions.

connection with the offering, the CEL-SCI will issue approximately

15 million registered shares of common stock at a purchase price of

$0.10 per share. Concurrently in a private placement, the

Company will issue warrants to purchase up to 15 million shares of

its common stock. For each share of common stock purchased by an

investor, such investor in the private placement will receive from

the CEL-SCI an unregistered warrant to purchase one share of common

stock. The warrants have an exercise price of $0.12 per share,

will be exercisable upon the 6 month anniversary of the issue date,

and will expire five and a half years from the issue

& Renshaw, a unit of H.C. Wainwright & Co., LLC, is acting

as the exclusive placement agent in connection with the

intends to use the net proceeds from the offering for the Phase 3

clinical study and general corporate purposes.

shares of common stock described above (but not the warrants or the

shares of common stock underlying the warrants) are being offered

pursuant to a shelf registration statement (File No.

333-205444). Such shares of common stock may be offered only

by means of a prospectus, including a prospectus supplement,

forming a part of the effective registration

warrants described above were offered in a private placement under

Section 4(a)(2) of the Securities Act of 1933, as amended (the

Act ), and Regulation D promulgated thereunder and,

along with the shares of common stock underlying the warrants, have

not been registered under the Act, or applicable state securities

laws. Accordingly, the warrants and underlying shares of common

stock may not be offered or sold in the United States except

pursuant to an effective registration statement or an applicable

exemption from the registration requirements of the Act and such

applicable state securities laws.

prospectus supplement and the accompanying prospectus relating to

the offering will be filed with the SEC and will be available on

the SEC's website at http://www.sec.gov. Copies of the

prospectus supplement, when filed with the SEC, and accompanying

prospectus relating to this offering may also be obtained from H.C.

Wainwright & Co., LLC, by emailing placements@hcwco.com or by

calling 646-975-6996.

press release shall not constitute an offer to sell or the

solicitation of an offer to buy any of the securities described

herein, nor shall there be any sale of these securities in any

state or jurisdiction in which such offer, solicitation or sale

would be unlawful prior to registration or qualification under the

securities laws of any such state or jurisdiction.

About CEL-SCI Corporation

work is focused on finding the best way to activate the immune

system to fight cancer and infectious diseases. Its lead

investigational immunotherapy, Multikine* (Leukocyte Interleukin,

Injection), is currently being studied in a pivotal Phase 3

clinical trial as a potential neoadjuvant treatment for patients

with squamous cell carcinoma of the head and neck. Subject to the

partial clinical hold, the study was designed with the objective

that, if the study endpoint, which is an improvement in overall

survival of the subjects treated with the Multikine treatment

regimen plus the current standard of care (SOC) as compared to

subjects treated with the current SOC only, is satisfied, the study

results will be used to support applications that the Company plans

to submit to regulatory agencies in order to seek commercial

marketing approvals for Multikine in major markets around the

world. Additional clinical indications for Multikine that are being

investigated include the treatment of cervical dysplasia in HIV/HPV

co-infected women, and the treatment of peri-anal warts in HIV/HPV

co-infected men and women. A Phase 1 trial of the former indication

(treatment of cervical dysplasia in HIV/HPV co-infected women) has

been completed at the University of Maryland. The latter indication

(treatment of peri-anal warts in HIV/HPV co-infected men and women)

is being studied in a Phase 1 trial at the University of

California, San Francisco. CEL-SCI has patents on Multikine from

the US, Europe, China, and Japan.

is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope

Antigen Presentation System) technology for the potential treatment

of pandemic influenza in hospitalized patients and as a potential

vaccine for the treatment of rheumatoid arthritis.

Company has operations in Vienna, Virginia, and in/near Baltimore,

Forward-Looking Statements

press release contains forward-looking statements within the

meaning of Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended.

When used in this press release, the words "intends," "believes,"

"anticipated," "plans" and "expects," and similar expressions, are

intended to identify forward-looking statements. Such statements

are subject to risks and uncertainties that could cause actual

results to differ materially from those projected. Such statements

include, but are not limited to, statements about the terms,

expected proceeds, use of proceeds and closing of the offering.

Factors that could cause or contribute to such differences include,

an inability to duplicate the clinical results demonstrated in

clinical studies, timely development of any potential products that

can be shown to be safe and effective, receiving necessary

regulatory approvals, difficulties in manufacturing any of the

Company's potential products, inability to raise the necessary